Related Experiment Video
Updated: Sep 13, 2025

Immunometabolic Circuits in Infection for Advancing Host Directed Therapies
Published on: September 13, 2024
The Clinical Value of Inflammatory Indicators at the Time of Secondary Infection After Treatment With Tocilizumab: A
Dena Firouzabadi1,2, Amirreza Dehghanian3,4, Sahar DehghanKhalili5
1Department of Clinical Pharmacy, School of Pharmacy Shiraz University of Medical Sciences Shiraz Iran.
Background And Aims:
Tocilizumab, an anti-inflammatory agent used in severe COVID-19 infection, is known to inhibit the Interleukin 6 receptor and reduce C-reactive protein (CRP) resulting in an increased risk of secondary infections. However, the trend of secondary infection and the relative inflammatory response after tocilizumab use has been reported variably.
Methods:
In this observational cross-sectional study, the time to normalization of CRP, rate of secondary infections, significance of infection indicators (CRP and white blood cell (WBC) count) at the time of secondary infections, length of intensive care unit (ICU) stay, and survival rate were evaluated in patients with severe COVID-19 infection after tocilizumab use.
Results:
A total of 216 patients (118 tocilizumab receivers vs. 98 nonreceivers) were included in this study. A higher rate of blood-stream infection (p 0.02), shorter ICU stay (p < 0.001) regardless of tocilizumab dose, and a slower rate of CRP normalization (p 0.009) were observed for tocilizumab receivers. The survival rate was not different between the two groups. A rise in CRP level was absent for tocilizumab receivers (p < 0.001) at the time of developing a secondary infection, while elevated WBC count was evident for both groups without any significant difference.
Conclusion:
Tocilizumab can increase the risk of secondary infections, while CRP levels may remain suppressed at the time. Therefore, CRP may not be suggested as a reliable marker of infection in tocilizumab users, although WBC count may remain a consistent value in confirming secondary infections in this population.
More Related Videos
06:37Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
Published on: September 15, 2023
09:54Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
Published on: May 22, 2020
Related Concept Videos
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Myocarditis II: Clinical Features and Diagnostic Tests
Pericarditis II: Clinical Features and Diagnostic Tests
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Acute Pyelonephritis II: Diagnostic Studies and Management